Skip to content

The HALT Hepatitis study

The HALT study: effectiveness of testing for, and treatment of, hard-to-reach groups for hepatitis B virus and hepatitis C virus in England

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN24707359
Enrollment
660
Registered
2012-11-15
Start date
2013-01-01
Completion date
Unknown
Last updated
2019-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C virus (HCV) or B virus (HBV) Infections and Infestations Acute hepatitis B, Acute hepatitis C

Interventions

Current interventions as of 06/02/2014: Screening of hard-to-reach individuals, random allocation of those infected with HCV to either peer support and accompanied referrals or normal

Sponsors

University College London (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Homeless or substance misusing individuals

Exclusion criteria

Exclusion criteria: 1. Individuals unable to give informed consent 2. Under 16 years of age

Design outcomes

Primary

MeasureTime frame
Current primary outcome measures as of 06/12/2012: 1. Cost effectiveness evaluation of the interventions 2. Successfully reaching an appropriate clinical endpoint for those HCV infected Previous primary outcome measures until 06/12/2012: 1. Cost effectiveness evaluation of the interventions 2. Successful completion of full HCV clinical diagnosis

Secondary

MeasureTime frame
Current secondary outcome measures as of 06/12/2012: 1. Sustained virological response to HCV treatment 2. Successfully reaching an appropriate clinical endpoint, full diagnosis and commencement of treatment, where appropriate, for those HBV infected 3. Proportion of hard-to-reach with adequate immune response to HBV vaccine 4. Factors influencing lack of vaccine uptake Previous secondary outcome measures until 06/12/2012: 1. Sustained virological response to HCV treatment 2. Successful full HBV clinical diagnosis and commencement of treatment 3. Proportion of hard-to-reach with adequate immune response to HBV vaccine 4. Factors influencing lack of vaccine uptake

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 3, 2026